Shandong Sito Bio-technology Co., Ltd. (SZSE:300583) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Shandong Sito Bio-technology Co., Ltd. (SZSE:300583) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Most readers would already be aware that Shandong Sito Bio-technology's (SZSE:300583) stock increased significantly by 23% over the past week. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current share price momentum can be maintained. In this article, we decided to focus on Shandong Sito Bio-technology's ROE.
大多数读者已经意识到,山东赛托生物科技(深交所代码:300583)的股票在过去一周大幅上涨了23%。但是该公司的关键财务指标似乎各不相同,这使我们质疑该公司目前的股价势头能否保持下去。在本文中,我们决定重点关注山东赛托生物科技的投资回报率。
Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
股本回报率或投资回报率是股东需要考虑的重要因素,因为它可以告诉他们资本再投资的有效性。简而言之,投资回报率显示了每美元从其股东投资中产生的利润。
Check out our latest analysis for Shandong Sito Bio-technology
查看我们对山东赛托生物科技的最新分析
How Do You Calculate Return On Equity?
你如何计算股本回报率?
ROE can be calculated by using the formula:
ROE 可以通过以下公式计算:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回报率 = 净利润(来自持续经营业务)÷ 股东权益
So, based on the above formula, the ROE for Shandong Sito Bio-technology is:
因此,根据上述公式,山东赛拓生物科技的投资回报率为:
3.4% = CN¥71m ÷ CN¥2.1b (Based on the trailing twelve months to September 2023).
3.4% = 7.1亿元人民币 ¥210亿元人民币(基于截至2023年9月的过去十二个月)。
The 'return' refers to a company's earnings over the last year. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.03 in profit.
“回报” 是指公司去年的收益。这意味着,公司每获得价值1元人民币的股东权益,就会产生0.03CN的利润。
What Is The Relationship Between ROE And Earnings Growth?
投资回报率与收益增长之间有什么关系?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.
我们已经确定,投资回报率是衡量公司未来收益的有效盈利指标。根据公司选择将多少利润进行再投资或 “保留”,我们便能够评估公司未来创造利润的能力。假设其他条件都一样,与功能不相同的公司相比,具有更高股本回报率和更高利润保留率的公司通常具有更高的增长率。
Shandong Sito Bio-technology's Earnings Growth And 3.4% ROE
山东赛托生物科技的收益增长和3.4%的投资回报率
As you can see, Shandong Sito Bio-technology's ROE looks pretty weak. Not just that, even compared to the industry average of 8.7%, the company's ROE is entirely unremarkable. Therefore, it might not be wrong to say that the five year net income decline of 15% seen by Shandong Sito Bio-technology was possibly a result of it having a lower ROE. We reckon that there could also be other factors at play here. For instance, the company has a very high payout ratio, or is faced with competitive pressures.
如你所见,山东赛托生物科技的投资回报率看起来相当疲软。不仅如此,即使与8.7%的行业平均水平相比,该公司的投资回报率也完全不起眼。因此,说山东赛托生物科技五年来净收入下降15%可能是其投资回报率较低的结果,这可能没有错。我们认为,这里可能还有其他因素在起作用。例如,该公司的支付率非常高,或者面临竞争压力。
So, as a next step, we compared Shandong Sito Bio-technology's performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 11% over the last few years.
因此,下一步,我们将山东赛拓生物科技的表现与行业进行了比较,失望地发现,尽管该公司一直在缩减收益,但该行业在过去几年中一直以11%的速度增长收益。
![past-earnings-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20231102/0-06b2d25aa6e21a56654dd264097dcfd5-0-71a9a88c4913497244843abcae660e72.png/big)
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. What investors need to determine next is if the expected earnings growth, or the lack of it, is already built into the share price. This then helps them determine if the stock is placed for a bright or bleak future. If you're wondering about Shandong Sito Bio-technology's's valuation, check out this gauge of its price-to-earnings ratio, as compared to its industry.
赋予公司价值的基础在很大程度上与其收益增长息息相关。投资者接下来需要确定的是,预期的收益增长或缺乏收益增长是否已经包含在股价中。然后,这可以帮助他们确定股票是面向光明还是黯淡的未来。如果你想知道山东赛托生物科技的估值,可以看看这个衡量其市盈率与行业比较的指标。
Is Shandong Sito Bio-technology Making Efficient Use Of Its Profits?
山东赛托生物科技是否在有效利用其利润?
When we piece together Shandong Sito Bio-technology's low three-year median payout ratio of 3.3% (where it is retaining 97% of its profits), calculated for the last three-year period, we are puzzled by the lack of growth. The low payout should mean that the company is retaining most of its earnings and consequently, should see some growth. So there might be other factors at play here which could potentially be hampering growth. For instance, the business has faced some headwinds.
当我们把过去三年计算得出的山东赛托生物科技的三年期中位数派息率很低,为3.3%(保留了97%的利润)时,我们对增长乏力感到困惑。低派息应该意味着该公司保留了大部分收益,因此应该会有所增长。因此,这里可能还有其他因素在起作用,这些因素可能会阻碍增长。例如,该业务面临一些阻力。
Additionally, Shandong Sito Bio-technology has paid dividends over a period of six years, which means that the company's management is rather focused on keeping up its dividend payments, regardless of the shrinking earnings.
此外,山东赛托生物科技已在六年内派发了股息,这意味着无论收益如何减少,该公司的管理层都将注意力集中在维持股息支付上。
Summary
摘要
In total, we're a bit ambivalent about Shandong Sito Bio-technology's performance. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. Wrapping up, we would proceed with caution with this company and one way of doing that would be to look at the risk profile of the business. Our risks dashboard would have the 4 risks we have identified for Shandong Sito Bio-technology.
总的来说,我们对山东赛托生物科技的表现有些矛盾。尽管该公司的利润保留率确实很高,但其低回报率可能阻碍了其收益增长。总而言之,我们将谨慎对待这家公司,做到这一点的一种方法是研究业务的风险状况。我们的风险仪表板将包含我们为山东赛托生物科技确定的4种风险。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。